New pill shows promise for Hard-to-Treat cancers in early trial

NCT ID NCT06846099

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called RP903 in 69 people with advanced solid tumors (like ovarian, breast, or cervical cancer) who had run out of standard options. The main goals were to check safety, find the best dose, and see if the drug shrinks tumors. It is an early-phase trial, so results will guide future studies rather than offer a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Affiliated Cancer Hospital of Fudan University

    Shanghai, China

  • Affiliated Hospital of Jining Medical College

    Jining, China

  • Beijing Cancer Hospital

    Beijing, China

  • Ceneral Hosipital of Ningxia Medical University

    Yinchuan, China

  • Chongqing University Cancer Hospital

    Chongqing, China

  • Fujian Cancer Hospital

    Fuzhou, China

  • Fujian Medical University Union Hospital

    Fuzhou, China

  • Guangxi Medical University Cancer Hospital

    Nanning, China

  • Harbin Medical University Cancer Hospital

    Harbin, China

  • Henan Cancer Hospital

    Zhengzhou, China

  • Hubei Cancer Hospital

    Wuhan, China

  • Jilin Cancer Hospital

    Changchun, China

  • Jilin University First Hospital

    Changchun, China

  • Liaoning Cancer Hospital&Institute

    Shenyang, China

  • Linyi Cancer Hospital

    Linyi, China

  • Shandong Cancer Hospital & Institute

    Jinan, China

  • Sichuan Cancer Hospital

    Chengdu, China

  • Sir Run Run Shaw Hospital

    Hangzhou, China

  • Suining Central Hospital

    Suining, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.